Monopar Therapeutics announced the filing of a provisional patent covering new therapeutic radiopharmaceuticals based on a family of linkers used to connect radioisotopes with targeting agents, including Monopar’s uPAR targeting antibody MNPR-101. Highlights of the patent filing include: Composition of Matter: Claims cover a family of linkers, as well as Monopar’s uPAR targeting agents linked with these along with therapeutic radioisotopes; Stability and Biodistribution: These proprietary new linkers have been created to enhance the stability and biodistribution of Monopar’s array of therapeutic radiopharmaceuticals; Versatility: The newly developed linker family works with a wide range of isotopes and targeting molecules, including small molecules/peptides and antibodies.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR:
- Monopar Therapeutics initiated with a Buy at Rodman & Renshaw
- Monopar Therapeutics initiates Phase 1a trial for MNPR-101-Lu
- Monopar Therapeutics Launches Phase 1a uPAR-Targeted Cancer Trial
- Monopar Therapeutics Reports Positive MNPR-101-Zr Trial Results
- Monopar Therapeutics announces early human clinical data for MNPR-101-Zr